0001217234-25-000063
SEC filingRevenue grew 21% to $100.1M driven by testing services volume; net income turned positive at $1.7M.
In Q3 2025, total revenue increased 21% year-over-year to $100.1 million, driven primarily by a 19% rise in testing services revenue to $72.2 million on volume of 50,300 tests (+13% YoY). Product revenue grew 22% to $12.5 million on higher sales of NGS-based kitted solutions, while patient and digital solutions revenue surged 30% to $15.4 million, fueled by Ottr software adoption and pharmacy sales. Gross margin improved to 69.4% from 66.7%, as cost of testing services grew slower than revenue (+9% vs +19%) and product cost declined 9% due to manufacturing efficiencies. Operating loss narrowed to $0.2 million from $13.7 million, and net income turned positive at $1.7 million compared to a net loss of $10.6 million, a $12.3 million swing. Key expense drivers included a 23% increase in sales and marketing (personnel costs) and a 10% decrease in G&A (lower stock-based compensation, partially offset by a $2.3M impairment charge).
Testing services remains the core growth engine, contributing 72% of total revenue. Revenue growth outpaced volume growth (19% vs 13%), indicating higher revenue per test from improved collections. Product revenue accelerated to 22% growth from 12% share, driven by NGS kit conversions. Patient and digital solutions grew 30% and now represent 15% of revenue, with momentum from Ottr software and TTP pharmacy. All segments improved profitability at the gross margin level, with product gross margin expanding due to lower input costs.
Management does not provide explicit financial guidance but highlights a strong liquidity position: $194.2 million in cash and marketable securities, no debt, and an authorized $50 million share repurchase program ($24.4 million remaining). They expect existing cash and operating cash flows to fund operations for the next 12 months. Key strategic priorities include growing testing volumes, expanding digital solutions, and advancing R&D pipeline (e.g., AlloCell). The $5.7 million litigation settlement (nine months) and $2.3 million impairment are non-recurring, and stock-based compensation is expected to remain significant. No forward-looking revenue or margin targets are provided.